Related Experiment Video

Updated: Aug 10, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

Adagrasib: First Approval

Sohita Dhillon1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 10, 2023
PubMed

Insights

Adagrasib is a new KRAS G12C inhibitor approved for non-small cell lung cancer (NSCLC). This targeted therapy offers a new treatment option for patients with this specific genetic mutation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • KRAS G12C mutations are key drivers in various solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
  • Targeted therapies inhibiting KRAS G12C offer a promising approach to cancer treatment.
  • Adagrasib is a potent, irreversible small molecule inhibitor specifically designed for the KRAS G12C mutant isoform.

Purpose of the Study:

  • To summarize the development milestones of adagrasib.
  • To highlight the first FDA approval of adagrasib for KRAS G12C-mutated NSCLC.
  • To provide an overview of adagrasib's mechanism of action and ongoing clinical development.

Main Methods:

  • Review of preclinical and clinical development data for adagrasib.
  • Analysis of regulatory submission and approval process in the USA.
  • Summary of adagrasib's mechanism of action, including covalent binding to KRAS G12C.

Main Results:

  • Adagrasib received accelerated FDA approval in December 2022 for adults with KRAS G12C-mutated locally advanced or metastatic NSCLC.
  • Approval was based on objective response rate and duration of response.
  • Adagrasib is under regulatory review in the EU for NSCLC and in development for CRC in the US.

Conclusions:

  • Adagrasib represents a significant advancement in targeted therapy for KRAS G12C-mutated NSCLC.
  • The drug's development highlights the success of precision medicine in oncology.
  • Continued clinical trials are essential to confirm clinical benefit and expand indications.

More Related Videos

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
609
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
578
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
806
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
900
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
953
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
224